President Trump has greenlit a plan to oust FDA Commissioner Marty Makary, exposing deep rifts in his administration’s push for a streamlined agency over entrenched bureaucracy.
Story Snapshot
- Trump approved firing plan after Makary resisted approving flavored e-cigarettes despite direct presidential pressure.
- Tensions stem from drug rejections and staff exits, frustrating biopharma and vaping industries.
- No termination date set; Trump denied knowledge publicly, leaving Makary’s fate in cliffhanger status.
- Move signals Trump’s determination to align FDA with America First priorities, cutting red tape for innovation.
Timeline of the Conflict
Marty Makary took office as FDA Commissioner on March 25, 2025, after Senate confirmation. By November 2025, the Trump administration eyed his replacement amid early policy clashes. Tensions peaked in early May 2026 when White House officials still voiced support. On May 6, FDA approved flavored e-cigarettes following Trump’s meeting with R.J. Reynolds executives. The Wall Street Journal reported on May 8 that Trump signed off on the firing plan.
Key Policy Flashpoints
Makary, a Johns Hopkins surgeon, resisted Trump’s push for fruit-flavored vapes, citing youth health risks despite industry lobbying. Broader disputes involved rejecting Replimune’s RP1 melanoma therapy, irking biopharma leaders. Deputy Vinay Prasad, Makary’s ally, resigned last week after similar decisions. These moves blocked what advisers called essential approvals, contrasting Trump’s vision for a “smarter FDA” that prioritizes American innovation over obstructive regulation.
Stakeholders and Power Plays
President Trump holds final authority, motivated by policy wins and industry pressure. HHS Secretary Robert F. Kennedy Jr. joined calls to remove Makary. Vaping firms like R.J. Reynolds lobbied directly, while biopharma criticized rejections as harmful delays. Potential successors include Kyle Dantas, Stephen Hahn, and Brett Pritt—conventional picks promising stability and faster approvals aligned with limited-government principles.
On May 9, Trump told reporters “Know nothing about it,” dodging questions while Axios described the situation as a “cliffhanger.” Makary remains listed on the FDA site, with no execution date announced. White House shifts from May 6 praise (“Marty’s great”) highlight internal drama fueling perceptions of deep state resistance.
trump approves plan to fire fda commissioner marty makary, sources say https://t.co/n3HMEtHtOi
— John Miles (@jmiles7291) May 11, 2026
Implications for FDA and America
Short-term uncertainty halts drug and vape decisions, rattling biopharma stocks and pending approvals. Long-term, a compliant leader could accelerate innovations, reducing barriers that stifle economic growth. Critics decry eroding independence, but supporters see it as curbing unelected bureaucrats who prioritize agendas over public needs. This saga underscores bipartisan frustration with federal overreach, echoing calls for accountability in a government failing everyday Americans.
Sources:
Trump approves plan to fire FDA Commissioner Marty Makary, sources say (CBS News)
FDA cliffhanger: Trump approves plan to fire Makary (Axios)
Trump responds to reports FDA chief could be fired: ‘Know nothing’ (Fox News)
Makary to leave as FDA commissioner: White House source (Politico)
Trump Signs Off on Plan to Oust Embattled FDA Commissioner Marty Makary: Report (BioSpace)
